Extracellular Vesicles From IFN-γ-Primed Mesenchymal Stem Cells Repress Atopic Dermatitis In Mice

    December 2022 in “ Journal of Nanobiotechnology ”
    Jimin Kim, Seul Ki Lee, Minyoung Jung, Seon‐Yeong Jeong, Haedeun You, Ji‐Yeon Won, Sang-Deok Han, Hye Jin Cho, Somi Park, Joonghoon Park, Tae Min Kim, Soo Kim
    TLDR Stem cell vesicles reduced eczema symptoms in mice safely.
    The study demonstrated that extracellular vesicles (EVs) derived from IFN-γ-primed mesenchymal stem cells effectively repressed atopic dermatitis (AD) in mice. These EVs reduced inflammation, itching, and improved skin barrier function by inhibiting Th2 cytokine receptors and their signaling pathways. The treatment decreased immune cell proliferation and proinflammatory cytokines, suggesting a promising cell-free therapeutic strategy for AD with fewer side effects. The study involved 5 mice per group and showed no adverse effects on cell viability, indicating the safety and efficacy of this approach.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results